Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACP3 | P15309 | 1/20 | 0.45 |
| ▸ | CARM1 | Q86X55 | 1/20 | 0.42 |
| ▸ | PRMT6 | Q96LA8 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
| ▸ | ADAMTS5 | Q9UNA0 | 1/20 | 0.39 |
| ▸ | PSMB5 | P28074 | 1/20 | 0.38 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.38 |
| ▸ | HPGD | P15428 | 2/20 | 0.38 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.38 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.38 |
| ▸ | BTN3A1 | O00481 | 1/20 | 0.38 |
| ▸ | OGG1 | O15527 | 1/20 | 0.38 |
| ▸ | HTR1B | P28222 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15486994 | 1.00 | ACP3 (0.45) | ACP3CARM1PRMT6KMT2AMAPT | |
| SCHEMBL15720902 | 0.89 | ACP3 (0.43) | ACP3CARM1PRMT6KMT2AADAMTS5 | |
| SCHEMBL1027922 | 0.85 | ALDH1A1 (0.40) | CARM1PRMT6KMT2AMAPTPSMB5 | |
| SCHEMBL3977464 | 0.85 | ALDH1A1 (0.40) | CARM1PRMT6KMT2AMAPTPSMB5 | |
| SCHEMBL722344 | 0.83 | PPARG (0.42) | KMT2APSMB5MEN1KDM4EALDH1A1 | |
| SCHEMBL15720921 | 0.83 | CYP2D6 (0.46) | KMT2AMAPK1KDM4EALDH1A1HPGD | |
| SCHEMBL15721086 | 0.83 | KMT2A (0.44) | ACP3KMT2AMAPTL3MBTL1MEN1 | |
| SCHEMBL1028181 | 0.82 | BTN3A1 (0.40) | CARM1PRMT6KMT2AL3MBTL1MAPK1 | |
| SCHEMBL1786739 | 0.81 | BTN3A1 (0.41) | KMT2AL3MBTL1MAPK1KDM4EALDH1A1 | |
| SCHEMBL15487036 | 0.81 | ALDH1A1 (0.39) | CARM1PRMT6KMT2AMAPK1MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220033433-A1 | PROCESS FOR PREPARING NUCLEOSIDE PRODRUGS | UNIVERSITY COLLEGE CARDIFF CONSULTANTS LIMITED (GB) | 2022-02-03 | — | — | US | disclosed |
| US-11040997-B2 | Process for preparing nucleoside prodrugs | NuCana plc (GB) | 2021-06-22 | — | — | US | disclosed |
| EP-3235824-B1 | MIXTURE OF RP/SP GEMCITABINE-[PHENYL-(BENZYLOXY-L-ALANINYL)]-PHOSPHATE | UNIV COLLEGE CARDIFF CONSULTANTS LTD (GB) | 2019-03-27 | — | — | EP | disclosed |
| US-20180273575-A1 | PROCESS FOR PREPARING NUCLEOSIDE PRODRUGS | NuCana plc (GB) | 2018-09-27 | — | — | US | disclosed |
| US-10005810-B2 | Process for preparing nucleoside prodrugs | UNIVERSITY COLLEGE CARDIFF CONSULTANTS LIMITED (GB) | 2018-06-26 | — | — | US | disclosed |
| EP-3235824-A1 | MIXTURE OF RP/SP GEMCITABINE-[PHENYL-(BENZYLOXY-L-ALANINYL)]-PHOSPHATE | University College Cardiff Consultants Limited (GB) | 2017-10-25 | — | — | EP | disclosed |
| EP-3150616-B1 | MIXTURE OF RP/SP GEMCITABINE-[PHENYL-(BENZYLOXY-L-ALANINYL)]-PHOSPHATE | UNIV COLLEGE CARDIFF CONSULTANTS LTD (GB) | 2017-05-10 | — | — | EP | disclosed |
| EP-3150616-A1 | MIXTURE OF RP/SP GEMCITABINE-[PHENYL-(BENZYLOXY-L-ALANINYL)]-PHOSPHATE | University College Cardiff Consultants Limited (GB) | 2017-04-05 | — | — | EP | disclosed |
| EP-2920192-B1 | PROCESS FOR PREPARING NUCLEOSIDE PRODRUGS | UNIV COLLEGE CARDIFF CONSULTANTS LTD (GB) | 2017-02-22 | — | — | EP | disclosed |
| US-20150291650-A1 | Process for Preparing Nucleoside Prodrugs | NuCana plc (GB) | 2015-10-15 | — | — | US | disclosed |
| EP-2920192-A1 | PROCESS FOR PREPARING NUCLEOSIDE PRODRUGS | University College Cardiff Consultants Limited (GB) | 2015-09-23 | — | — | EP | disclosed |
| WO-2014076490-A1 | PROCESS FOR PREPARING NUCLEOSIDE PRODRUGS | UNIVERSITY COLLEGE CARDIFF CONSULTANTS LIMITED (GB) | 2014-05-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11040997-B2 | Process for preparing nucleoside prodrugs | PNP, TYMP, SLC29A1 | ACP3 516/4885CARM1 2597/4885PRMT6 2484/4885 |
| US-20180273575-A1 | PROCESS FOR PREPARING NUCLEOSIDE PRODRUGS | PNP, MTAP, TYMP | ACP3 609/4885CARM1 2963/4885PRMT6 2420/4885 |
| US-20150291650-A1 | Process for Preparing Nucleoside Prodrugs | PNP, MTAP, TYMP | ACP3 777/4885CARM1 2834/4885PRMT6 2360/4885 |
| US-20220033433-A1 | PROCESS FOR PREPARING NUCLEOSIDE PRODRUGS | PNP, MTAP, TYMP | ACP3 609/4885CARM1 2963/4885PRMT6 2420/4885 |
| US-10005810-B2 | Process for preparing nucleoside prodrugs | PNP, TYMP, SLC29A1 | ACP3 574/4885CARM1 2497/4885PRMT6 2457/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.